Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What causes the antiphospholipid syndrome?

J T Merrill1

  • 1Division of Rheumatology, St. Luke's-Roosevelt Hospital Center, 432 West 58th Street, Antenucci Building, New York, NY 10019, USA. jtm5@columbia.edu

Current Rheumatology Reports
|July 27, 2001
PubMed
Summary

Antiphospholipid syndrome (APS) involves unpredictable blood clots. Autoantibodies in APS may expose hidden phospholipid epitopes, triggering immune responses and thrombosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantifying stratosphere-troposphere transport of ozone using balloon-borne ozonesondes, radar windprofilers and trajectory models.

Atmospheric environment (Oxford, England : 1994)·2020
Same author

A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus.

The British journal of dermatology·2019
Same author

The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients.

Lupus·2017
Same author

Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study.

Arthritis care & research·2015
Same author

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Annals of the rheumatic diseases·2015
Same author

Genetic association of CD247 (CD3ζ) with SLE in a large-scale multiethnic study.

Genes and immunity·2015

Area of Science:

  • Immunology
  • Hematology
  • Pathophysiology

Background:

  • Antiphospholipid syndrome (APS) is defined by recurrent thrombotic events.
  • The etiology of thrombosis in APS is multifactorial, involving autoantibodies that disrupt hemostasis.
  • Existing theories struggle to explain the diverse autoantibody effects in APS.

Purpose of the Study:

  • To propose an integrated theory for APS pathogenesis.
  • To explain how diverse autoantibodies contribute to thrombotic events in APS.
  • To elucidate the role of cellular processes in epitope exposure in APS.

Main Methods:

  • Review of existing literature on APS pathogenesis.
  • Analysis of the interaction between autoantibodies and phospholipid-binding proteins.
  • Hypothesizing the role of cellular inflammation and apoptosis in epitope presentation.

Main Results:

  • Cellular inflammation or apoptosis in blood vessels may alter phospholipid membranes.
  • This alteration exposes normally hidden epitopes on phospholipid-binding proteins.
  • Increased exposure of these epitopes enhances immune surveillance and potentially triggers thrombosis.

Conclusions:

  • An integrated theory suggests vascular cellular events expose critical phospholipid epitopes in APS.
  • This exposure is a key mechanism linking autoantibodies to thrombosis in APS.
  • Understanding this mechanism may lead to novel therapeutic strategies for APS.

Related Experiment Videos